We advised Sorrento Therapeutics on its $35 million public offering. Our services included advising the company through a reverse stock split to meet the Nasdaq’s share-price requirement for listing on the Capital Market, raising capital, and coordinating with the exchange to ensure completion of the uplisting.

Note: This work was performed prior to joining Stout.